Page last updated: 2024-12-10

quinoxyfen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

quinoxyfen: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

quinoxyfen : A member of the class of quinolines carrying two chloro substituents at positions 5 and 7 together with a 4-fluorophenoxy substituent at position 4. A fungicide used mainly to control powdery mildew in cereals. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3391107
CHEMBL ID1869863
CHEBI ID82040
SCHEMBL ID22257
MeSH IDM0445108

Synonyms (44)

Synonym
de 795
quinoxyfen [iso:bsi:ansi]
quinoline, 5,7-dichloro-4-(4-fluorophenoxy)-
legend
NCGC00163706-01
quinoxyfen
124495-18-7
5,7-dichloro-4-(4-fluorophenoxy)quinoline
NCGC00163706-02
NCGC00163706-04
NCGC00163706-03
hsdb 7946
ppc78j1vcw ,
unii-ppc78j1vcw
C18892
dtxsid2034881 ,
tox21_300844
cas-124495-18-7
NCGC00254747-01
dtxcid0014881
(5,7-dichloro-4-quinolyl) (4-fluorophenyl) ether
Q0093
FT-0674291
quinoxyfen [iso]
de-795
quintec
5,7-dichloro-4-quinolyl 4-fluorophenyl ether
quinoxyfen [mi]
SCHEMBL22257
chebi:82040 ,
CHEMBL1869863
AKOS025243116
KS-5368
J-516558
J-005085
quinoxyfen, pestanal(r), analytical standard
quinoxyfen 10 microg/ml in cyclohexane
quinoxyfen 10 microg/ml in acetonitrile
EX-A7271
CS-0078946
mfcd03265638
legend; de 795
Q961155
de795

Research Excerpts

Overview

Quinoxyfen is a fungicide of the phenoxyquinoline class used to control powdery mildew, Uncinula necator (Schw.) Burr. It has been commercially used for the control of B graminis in Europe since 1997.

ExcerptReferenceRelevance
"Quinoxyfen is a fungicide developed by Dow AgroSciences for the control of powdery mildew. "( Improved synthetic route to quinoxyfen photometabolite 2-chloro-10-fluorochromeno[2,3,4-de]quinoline.
Johnson, PL; Kister, J; Thornburgh, S, 2017
)
2.19
"Quinoxyfen is a fungicide of the phenoxyquinoline class used to control powdery mildew, Uncinula necator (Schw.) Burr. "( A Bayesian approach to assessing the uncertainty in estimating bioconcentration factors in earthworms--the example of quinoxyfen.
Capri, E; Fragoulis, G; Meregalli, G; Merli, A; Reeves, G; Stenberg, K; Tanaka, T, 2011
)
2.02
"Quinoxyfen is a surface-mobile fungicide from a new chemical class that has been commercially used for the control of B graminis in Europe since 1997."( Quinoxyfen--resistance management and sensitivity monitoring in wheat: 1995-2000.
Bernhard, U; Felsenstein, FG; Leader, A; Longhurst, C, 2002
)
2.48
"Quinoxyfen is a protectant fungicide that provides excellent control of many powdery mildew diseases. "( Sensitivity of Uncinula necator to quinoxyfen: evaluation of isolates selected using a discriminatory dose screen.
Green, EA; Gustafson, GD, 2006
)
2.05
"Quinoxyfen is a potent and effective fungicide, hitherto considered to control powdery mildew disease by perturbing signal transduction during early germling differentiation. "( Host perception and signal transduction studies in wild-type Blumeria graminis f. sp. hordei and a quinoxyfen-resistant mutant implicate quinoxyfen in the inhibition of serine esterase activity.
Baloch, R; Gurr, S; Gustafson, G; Lee, S; Skamnioti, P, 2008
)
2.01

Effects

ExcerptReferenceRelevance
"Quinoxyfen has been recently identified as a priority hazardous substance in the field of the European water policy. "( Assessment of quinoxyfen phototransformation pathways by liquid chromatography coupled to accurate mass spectrometry.
Bergamasco, R; Cela, R; Ferri, P; Ramil, M; Rodríguez, I; Vieira, AM, 2017
)
2.26

Toxicity

ExcerptReferenceRelevance
"Results obtained with the ANPP/CEB guideline allow the demonstration of significant differences between two slightly toxic products, a dichlofluanid 500 g kg(-1) kWP (Euparen) 50WP) and a quinoxyfen 250 g L(-1) SCC (Legend), and a highly toxic cymoxanil 60/mancozeb 200/folpet 275 g kg(-1) WP [Remiltine F Pepite) (RFP)], on the basis of bioassays conducted in the laboratory."( Suitability of two laboratory testing methods to evaluate the side effects of pesticides on Typhlodromus pyri Scheuten (Acari: Phytoseiidae).
Auger, P; Bonafos, R; Guichou, S; Kreiter, S, 2008
)
0.54
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antifungal agrochemicalAny substance used in acriculture, horticulture, forestry, etc. for its fungicidal properties.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
monofluorobenzenesAny member of the class of fluorobenzenes containing a mono- or poly-substituted benzene ring carrying a single fluorine substitutent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (30)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency35.57420.007215.758889.3584AID1224835
pregnane X receptorRattus norvegicus (Norway rat)Potency44.66840.025127.9203501.1870AID651751
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency54.94103.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency5.66550.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency8.70760.173734.304761.8120AID1346924
SMAD family member 3Homo sapiens (human)Potency8.70760.173734.304761.8120AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency54.84420.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency55.68740.000221.22318,912.5098AID1259243; AID1259247; AID588515; AID743042; AID743054; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency47.75340.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency25.32630.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency27.30600.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency50.68900.000214.376460.0339AID588533; AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency9.54820.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency21.43240.000817.505159.3239AID1159527; AID1159531; AID588544; AID588546
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency42.93170.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency44.66840.375827.485161.6524AID588526
pregnane X nuclear receptorHomo sapiens (human)Potency49.05030.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency44.00370.000229.305416,493.5996AID1259383; AID588514; AID743069; AID743075; AID743078; AID743079; AID743080
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency23.44510.001024.504861.6448AID588534; AID588535
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency23.04130.001019.414170.9645AID588536; AID743094; AID743140
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency19.80270.023723.228263.5986AID588543; AID743222; AID743241
aryl hydrocarbon receptorHomo sapiens (human)Potency68.58960.000723.06741,258.9301AID743085
thyroid stimulating hormone receptorHomo sapiens (human)Potency41.33540.001628.015177.1139AID1224843; AID1259385; AID1259395
activating transcription factor 6Homo sapiens (human)Potency2.45410.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency61.644819.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency56.56880.057821.109761.2679AID1159526; AID1159528
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency62.60840.000323.4451159.6830AID743065; AID743066; AID743067
heat shock protein beta-1Homo sapiens (human)Potency54.94100.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency20.76010.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
Cellular tumor antigen p53Homo sapiens (human)Potency68.58960.002319.595674.0614AID651631; AID720552
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID1104839Antifungal activity against Erysiphe necator biotype B assessed as number of spores at 0.5 g a.i./l applied 4 days post-inoculation measured after 14 days during cycle 1 by leaf-disk method (Rvb = 35.9 x 10'3 cm'-2)2010Pest management science, Dec, Volume: 66, Issue:12
Efficacy of fungicides with various modes of action in controlling the early stages of an Erysiphe necator-induced epidemic.
AID1104855Antifungal activity against Erysiphe necator biotype B assessed as number of spores at 0.5 g a.i./l applied 48 hr post-inoculation measured after 14 days by leaf-disk method (Rvb = 43.5 x 10'3 cm'-2)2010Pest management science, Dec, Volume: 66, Issue:12
Efficacy of fungicides with various modes of action in controlling the early stages of an Erysiphe necator-induced epidemic.
AID1104837Antifungal activity against Erysiphe necator biotype B assessed as number of spores at 0.5 g a.i./l applied 4 days post-inoculation measured after 14 days during cycle 2 by leaf-disk method (Rvb = 44.4 x 10'3 cm'-2)2010Pest management science, Dec, Volume: 66, Issue:12
Efficacy of fungicides with various modes of action in controlling the early stages of an Erysiphe necator-induced epidemic.
AID1104834Antifungal activity against Erysiphe necator biotype B assessed as disease severity at 0.5 g a.i./l applied 4 days post-inoculation measured immediately during cycle 1 by leaf-disk method relative to untreated-control2010Pest management science, Dec, Volume: 66, Issue:12
Efficacy of fungicides with various modes of action in controlling the early stages of an Erysiphe necator-induced epidemic.
AID1104816Antifungal activity against Erysiphe necator biotype B assessed as disease severity at 0.5 g a.i./l applied 13 days post-inoculation measured after 6 days during cycle 2 by leaf-disk method relative to untreated-control2010Pest management science, Dec, Volume: 66, Issue:12
Efficacy of fungicides with various modes of action in controlling the early stages of an Erysiphe necator-induced epidemic.
AID1104860Antifungal activity against Erysiphe necator biotype B assessed as disease severity at 0.5 g a.i./l applied 13 days post-inoculation measured after 14 days during cycle 2 by leaf-disk method relative to untreated-control2010Pest management science, Dec, Volume: 66, Issue:12
Efficacy of fungicides with various modes of action in controlling the early stages of an Erysiphe necator-induced epidemic.
AID1104849Antifungal activity against Erysiphe necator biotype B assessed as reduction in disease severity at 0.5 g a.i./l applied 48 hr post-inoculation measured after 14 days by leaf-disk method relative to untreated-control2010Pest management science, Dec, Volume: 66, Issue:12
Efficacy of fungicides with various modes of action in controlling the early stages of an Erysiphe necator-induced epidemic.
AID1104820Antifungal activity against Erysiphe necator biotype B assessed as number of spores at 0.5 g a.i./l applied 13 days post-inoculation measured after 14 days during cycle 2 by leaf-disk method (Rvb = 47.6 x 10'3 cm'-2)2010Pest management science, Dec, Volume: 66, Issue:12
Efficacy of fungicides with various modes of action in controlling the early stages of an Erysiphe necator-induced epidemic.
AID1104838Antifungal activity against Erysiphe necator biotype B assessed as AUDPC at 0.5 g a.i./l applied 4 days post-inoculation measured after 14 days during cycle 2 by leaf-disk method (Rvb = 844)2010Pest management science, Dec, Volume: 66, Issue:12
Efficacy of fungicides with various modes of action in controlling the early stages of an Erysiphe necator-induced epidemic.
AID1104830Antifungal activity against Erysiphe necator biotype B assessed as disease severity at 0.5 g a.i./l applied 4 days post-inoculation measured after 14 days during cycle 1 by leaf-disk method relative to untreated-control2010Pest management science, Dec, Volume: 66, Issue:12
Efficacy of fungicides with various modes of action in controlling the early stages of an Erysiphe necator-induced epidemic.
AID1104829Antifungal activity against Erysiphe necator biotype B assessed as reduction in disease severity at 0.5 g a.i./l applied 4 days post-inoculation measured after 11 days during cycle 2 by leaf-disk method relative to untreated-control2010Pest management science, Dec, Volume: 66, Issue:12
Efficacy of fungicides with various modes of action in controlling the early stages of an Erysiphe necator-induced epidemic.
AID1104821Antifungal activity against Erysiphe necator biotype B assessed as AUDPC at 0.5 g a.i./l applied 13 days post-inoculation measured after 14 days during cycle 2 by leaf-disk method (Rvb = 654)2010Pest management science, Dec, Volume: 66, Issue:12
Efficacy of fungicides with various modes of action in controlling the early stages of an Erysiphe necator-induced epidemic.
AID1104828Antifungal activity against Erysiphe necator biotype B assessed as reduction in AUDPC at 0.5 g a.i./l applied 4 days post-inoculation measured after 11 days during cycle 2 by leaf-disk method relative to untreated-control2010Pest management science, Dec, Volume: 66, Issue:12
Efficacy of fungicides with various modes of action in controlling the early stages of an Erysiphe necator-induced epidemic.
AID1104826Antifungal activity against Erysiphe necator biotype B assessed as reduction in mycelial growth at 0.5 g a.i./l applied 4 days post-inoculation measured after 11 days during cycle 2 by leaf-disk method relative to untreated-control2010Pest management science, Dec, Volume: 66, Issue:12
Efficacy of fungicides with various modes of action in controlling the early stages of an Erysiphe necator-induced epidemic.
AID1104840Antifungal activity against Erysiphe necator biotype B assessed as AUDPC at 0.5 g a.i./l applied 4 days post-inoculation measured after 14 days during cycle 1 by leaf-disk method (Rvb = 695.6)2010Pest management science, Dec, Volume: 66, Issue:12
Efficacy of fungicides with various modes of action in controlling the early stages of an Erysiphe necator-induced epidemic.
AID1104854Antifungal activity against Erysiphe necator biotype B assessed as AUDPC at 0.5 g a.i./l applied 48 hr post-inoculation measured after 14 days by leaf-disk method (Rvb = 394)2010Pest management science, Dec, Volume: 66, Issue:12
Efficacy of fungicides with various modes of action in controlling the early stages of an Erysiphe necator-induced epidemic.
AID1104827Antifungal activity against Erysiphe necator biotype B assessed as reduction in sporulation at 0.5 g a.i./l applied 4 days post-inoculation measured after 11 days during cycle 2 by leaf-disk method relative to untreated-control2010Pest management science, Dec, Volume: 66, Issue:12
Efficacy of fungicides with various modes of action in controlling the early stages of an Erysiphe necator-induced epidemic.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (50.00)29.6817
2010's8 (44.44)24.3611
2020's1 (5.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.63 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index46.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (5.56%)4.05%
Observational0 (0.00%)0.25%
Other17 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]